Albert Bourla, CEO of Pfizer, wrote directly to Friedrich Merz, the German Chancellor, this week. The letter was not routine lobbying. It was a warning: the cumulative weight of European pricing policy — AMNOG, MFN benchmarking, EU HTA reform — is making Germany, Europe's largest pharmaceutical market, an increasingly unattractive place to launch innovative medicines.
Vas Narasimhan at Novartis has made the same argument. Pascal Soriot at AstraZeneca has been making it publicly for months. Eli Lilly and Boehringer Ingelheim have gone further — withdrawing products from German tendering rather than accept reference prices that would anchor their global pricing baskets at a level that makes the rest of the world's negotiations harder.
"This is not sentiment. When CEOs write to chancellors and companies withdraw products from major markets, it is the market giving advance notice of what comes next."
The standard read of this moment is that pharma is pushing back on German AMNOG reforms. That is true, but it is the surface layer. The deeper read is that the architecture linking European prices to US commercial outcomes — through MFN's reference basket mechanisms — has changed the commercial calculus of a low European price in a way that did not exist three years ago.
A German AMNOG price used to be a German problem. Under GLOBE and GUARD, it is now an input into the ceiling available for US Medicare negotiation. Accepting a deeply discounted German price is no longer a European market access decision — it is a US revenue decision made in Berlin. That is a structural change in how the global pricing system works, and it is why the industry's response to German reforms looks different this cycle than it did in the last one.
The implication for assets currently in Phase 2 and Phase 3 is straightforward: the decisions being made now about evidence strategy, launch sequencing, and deal structure are being made in a system that has changed. Most planning assumptions have not caught up.
Go Ahead — De-Prioritise Europe. You Can't De-Prioritise the Exposure.
The Bourla letter was the signal. This piece examines the mechanism behind it — how MFN and EU HTA reform create a feedback loop between European pricing outcomes and US commercial ceilings, and what it means for the decisions companies are making right now.
Read the full analysis →